Because acute respiratory distress syn-drome (Figure 1) affects up to 150 000 patients and
causes 60 000 deaths each year in the United States, the interest in potential therapies for …

ABSTRACT INTRODUCTION Acute respiratory distress syndrome (ARDS) is a rapidly
progressing, inflammatory lung disease with a high mortality rate and no specific …

The acute respiratory distress syndrome (ARDS) is an important problem in critical care
medicine due to its relatively high incidence and substantial mortality. The complex series of …

Background: Evidence exploring the use of corticosteroids for acute respiratory distress
syndrome (ARDS) has targeted various stages of disease progression, from preventing …

Background Evidence‐based recommendations on the efficacy and safety of corticosteroids
in acute respiratory distress syndrome (ARDS) remain a therapeutic challenge. Findings …

The potential benefit and harm of using corticosteroids to manage acute respiratory distress
syndrome (ARDS) have been evaluated since the 1980s [1-8]. However, studies have …

The annual incidence of acute respiratory distress syndrome (ARDS) has been estimated at
150000 cases in the United States. 1 Although its outcome may have improved in the past 2 …

Introduction The effectiveness of corticosteroid therapy on the mortality of acute respiratory
distress syndrome (ARDS) remains under debate. We aimed to explore the grounds for the …

The first report in the literature of the acute respiratory distress syndrome (ARDS) presents
12 patients who developed acute hypoxemic respiratory failure in response to overwhelming …

Objective: Controversy remains as to whether low-dose corticosteroids can reduce the
mortality and morbidity of acute lung injury (ALI) or the acute respiratory distress syndrome …